Found: 6
Select item for more details and to access through your institution.
Safety and Immunogenicity of the Heterologous 2-Dose Ad26.ZEBOV, MVA-BN-Filo Vaccine Regimen in Health Care Providers and Frontliners of the Democratic Republic of the Congo.
- Published in:
- Journal of Infectious Diseases, 2024, v. 229, n. 4, p. 1068, doi. 10.1093/infdis/jiad350
- By:
- Publication type:
- Article
Persistence of immunological memory as a potential correlate of long-term, vaccine-induced protection against Ebola virus disease in humans.
- Published in:
- Frontiers in Immunology, 2023, p. 01, doi. 10.3389/fimmu.2023.1215302
- By:
- Publication type:
- Article
Monitoring of Adverse Events in Recipients of the 2-Dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in the UMURINZI Ebola Vaccination Campaign.
- Published in:
- Journal of Infectious Diseases, 2023, v. 227, n. 2, p. 268, doi. 10.1093/infdis/jiac283
- By:
- Publication type:
- Article
Safety, reactogenicity, and immunogenicity of a 2-dose Ebola vaccine regimen of Ad26.ZEBOV followed by MVA-BN-Filo in healthy adult pregnant women: study protocol for a phase 3 open-label randomized controlled trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Steady-state pharmacokinetics of rilpivirine under different meal conditions in HIV-1-infected Ugandan adults.
- Published in:
- Journal of Antimicrobial Chemotherapy (JAC), 2015, v. 70, n. 5, p. 1482, doi. 10.1093/jac/dku575
- By:
- Publication type:
- Article